Find your people Federal reform, state legalisation, and the shifting American cannabis economy.
The US Drug Enforcement Administration has asked its judge to recommend Schedule III after a landmark hearing. It is a major institutional shift, but not yet a final nationwide rule.
Q1 2026 data projects US medical cannabis market to exceed $45 billion by 2027, with record sales but price compression squeezing multi-state operators in mature western states.
Delaware became the 25th US state to legalise adult-use cannabis sales on 15 April 2026, with three retailers opening under a social equity-focused licensing programme.
Bipartisan legislation and a $25 million VA funding push could finally allow doctors to recommend medical cannabis to veterans in legal states.
The SAFE Banking Act has been reintroduced in the US Senate with a key Section 280E reform amendment, advancing through committee hearings with bipartisan support.
FDA releases March 2026 draft guidance on hemp-derived CBD, proposing a 20 mg daily cap and strict labelling rules for a $4B+ market.
DEA hearings in March 2026 weigh historic move of cannabis to Schedule III, with HHS and DEA officials clashing over medical use and public health risks.